LeMaitre Vascular, Inc. (LMAT) Cash Flow Statement

The ratio of operating cash flow to net income has been erratic, dipping to 0.94 in Q2 2026 despite strong net income growth. This appears driven by negative working capital changes, particularly inventory builds for biological tissues and receivables timing, which may indicate that reported earnings are not yet translating into cash at the same pace. Investors should monitor whether this is a seasonal pattern or a structural shift as the company expands internationally.

The trajectory of free cash flow has been upward, with a notable spike in Q3 2025 driven by favorable working capital inflows. While Q2 2026 FCF margin of 19.4% is below the peak, it remains well above the 2024 average, suggesting that the company is achieving operating leverage despite increased investment in sales force and warehouse expansions. The sustained double-digit revenue growth, as noted in prior analysis, appears to be translating into higher cash generation, though the recent moderation warrants monitoring.

Capital expenditures have been modest, averaging around 3% of revenue, which is consistent with a manufacturing model that relies on specialized processes rather than heavy equipment. The recent increase in CapEx to 4.2% in Q1 2026 may reflect investments in warehouse expansions, but the overall capital intensity remains low, allowing the company to generate substantial free cash flow. This suggests that growth is being funded organically without straining the balance sheet.

The persistent negative working capital changes, particularly in Q1 quarters, suggest that the company is deliberately building inventory of biological tissues and components to mitigate supply chain risks, as noted in company intelligence. This strategy appears to be a deliberate choice to ensure product availability, but it also creates volatility in operating cash flow. The positive working capital inflow in Q3 2025 suggests that some of this inventory was monetized, but the overall trend indicates a need for careful monitoring of inventory turnover.

Capital deployment has been conservative, with dividends increasing steadily and minimal share repurchases. The company's substantial cash position of $376M, as highlighted in recent context, provides ample liquidity for potential tuck-in acquisitions, but the current deployment suggests a preference for returning cash to shareholders via dividends. This approach aligns with the company's fortress balance sheet and may indicate a disciplined M&A strategy, though investors should watch for any large acquisitions that could alter this pattern.

The cumulative gap between operating cash flow and net income is positive, suggesting that earnings are backed by actual cash generation. This is a favorable signal for earnings quality, as it implies that the company is not relying on aggressive accruals to boost reported profits. The divergence is particularly notable in quarters like Q3 2025, where OCF/NI reached 1.66, indicating strong cash conversion. However, the recent quarters with sub-1.0 ratios warrant attention, as they may signal a shift in working capital dynamics.